Next-Generation vaccine adjuvants: NIAID perspective on mechanistic insights and emerging strategies

Vaccine adjuvants play a central role in shaping the magnitude, quality, and durability of vaccine-induced immune responses, yet their rational design and selection remain major challenges. Although the adjuvant repertoire has expanded substantially over the past two decades, this growth has not yielded broadly predictive frameworks capable of matching adjuvants to antigens, vaccine platforms, disease contexts, or populations. Advances in innate immunology and systems vaccinology have revealed early immune signatures associated with vaccine efficacy, but translating these insights into generalizable design rules has proven difficult due to context dependence, population heterogeneity, and the complexity of immune pathways. To address these limitations, the Division of Allergy, Immunology, and Transplantation (DAIT) within the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health, has established coordinated adjuvant discovery, development, and comparative research programs that emphasize standardized study designs, harmonized immune profiling, and cross-platform data integration that enable the systematic evaluation of adjuvant mechanisms and biological activities. Here, we examine conceptual and practical lessons emerging from DAIT/NIAID-supported programs and the adjuvant field more broadly, focusing on comparative immune profiling, adjuvant mimics, and combination adjuvants. Collectively, these efforts illustrate how harmonized datasets, shared infrastructure, and mechanism-guided analyses can transform adjuvant selection from an empirical process into a data-driven component of rational vaccine design, supporting precision immunomodulation across infectious, immunologic, and other non-infectious diseases.